Johnson & Johnson

Jim Cramer advises investors to temper enthusiasm for high-flying tech and AI stocks due to parabolic rally risks. He advocates for a diversified strategy, highlighting opportunities in undervalued companies. Cramer’s Charitable Trust recently invested in Johnson & Johnson, seeing value amidst negative sentiment. He stresses a balanced portfolio, mixing “hot” and “not hot” assets for long-term stability and growth.

Johnson & Johnson has partnered with the U.S. administration to lower drug prices and expand its domestic footprint. This agreement will provide millions of Americans with access to discounted pharmaceuticals and exempt these medicines from U.S. tariffs. The company is reinforcing its $55 billion U.S. investment, with plans for two new advanced manufacturing facilities for cell therapies and biologics, creating thousands of jobs and demonstrating a commitment to U.S.-based production and innovation.